

Form PTO-1449 (modified)		Atty. Docket No. CLFR:158US	Serial No. 10/663,573
<b>List of Patents and Publications for Applicant's</b> <b>INFORMATION DISCLOSURE STATEMENT</b> <small>(Use several sheets if necessary)</small>			
		Filing Date: September 16, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
AS	B6	WO 98/00111	01/08/98	WIPO	English

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
AS	C28	Burke, "Lipid bilayer partitioning and stability of camptothecin drugs," <i>Biochemistry</i> , 32:5352-5364, 1993.
AS	C29	Hinz <i>et al.</i> , "Pharmacokinetics of the <i>in Vivo</i> and <i>in Vitro</i> Conversion of 9-Nitro-20(S)-camptothecin to 9-Amino-20(S)-camptothecin in Humans, Dogs, and Mice," <i>Cancer Res.</i> , 54:3096-3100, 1994.

25730388.1

EXAMINER: /Aradhana Sasan/ DATE CONSIDERED: 01/17/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. <b>CLFR:158US</b>	Serial No. <b>10/663,573</b>
<b>List of Patents and Publications for Applicant's</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)		<b>Applicant</b> <b>J. Vernon Knight et al.</b>	
		Filing Date: <b>September 16, 2003</b>	Group: <b>1615</b>
<b>U.S. Patent Documents</b> <i>See Page I</i>	<b>Foreign Patent Documents</b> <i>See Page I</i>	<b>Other Art</b> <i>See Page I</i>	

### **U.S. Patent Documents**

<b>Exam. Init.</b>	<b>Ref. Des.</b>	<b>Document Number</b>	<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date of App.</b>
AS	A1	5,049,388	11/17/91	Knight et al.	424	450	07/21/89
	A2	5,422,344	06/06/95	Priell et al.	514	50	05/08/90
	A3	5,552,156	11/03/96	Burke	424	450	03/22/95
	A4	5,736,156	04/07/98	Burke	424	450	04/12/96
	A5	5,958,378	11/28/99	Waldrep et al.	424	45	10/16/96
↓	A6	6,090,407	07/18/00	Knight et al.	424	450	11/23/97
↓	A7	6,346,233	02/12/02	Knight et al.	424	45	07/17/00

### **Foreign Patent Documents**

<b>Exam. Init.</b>	<b>Ref. Des.</b>	<b>Document Number</b>	<b>Date</b>	<b>Country</b>	<b>Language</b>
AS	B1	DE 4430593C2	08/20/94	Germany	Abstract
	B2	WO 9318751	03/23/93	WIPO	English
	B3	WO 9426253	05/16/94	WIPO	English
↓	B4	WO 9605821	08/18/95	WIPO	Abstract
↓	B5	WO 9619199	12/20/95	WIPO	English

### **Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

<b>Exam. Init.</b>	<b>Ref. Des.</b>	<b>Citation</b>
AS	C1	"Chiron submits new drug application for pulminiq; inhaled form of cyclosporine could be first immunosuppressant indicated for chronic lung-transplant rejection," <a href="http://www.drugs.com/nda/pulminiq_041014.html">www.drugs.com/nda/pulminiq_041014.html</a> .
AS	C2	Abang et al., "The clinical pharmacology of topoisomerase I inhibitors," <i>Sem Hematol</i> , 35:13-21, 1998.

25695214.1

**EXAMINER:** /Aradhana Sasan/      **DATE CONSIDERED:** 01/17/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:158US	Serial No. 10/663,573
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)			
		Filing Date: September 16, 2003	Group: 1615
U.S. Patent Documents <i>See Page I</i>	Foreign Patent Documents <i>See Page I</i>	Other Art <i>See Page I</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
AS	C3	Ahmed <i>et al.</i> , "Influence of route of administration on [3h]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies," <i>Cancer Chemother Pharmacol.</i> , 39:122-130, 1996.
	C4	Anderson, "Delivery systems for immunomodulatory proteins and peptides," <i>BioDrugs</i> , 7:51-65, 1997.
	C5	Burckart <i>et al.</i> , "Lung deposition and pharmacokinetics of cyclosporine after aerosolization in lung transplant patients," <i>Pharmaceutical Research</i> , 20:252-256, 2003.
	C6	Chourpa <i>et al.</i> , "Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA," <i>Biochem</i> , 37:7284-7291, 1998.
	C7	Fresta <i>et al.</i> , "Evaluation and optimization of liposomes as delivery device for methotrexate," <i>Pharmazie</i> , 47:926-929, 1992.
	C8	Garcia-Carbonero <i>et al.</i> , "Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins," <i>Clin. Cancer Res.</i> , 8:641-661, 2002.
	C9	Giovanella <i>et al.</i> , "Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin," <i>Cancer Res.</i> , 51:3052-3055, 1991.
	C10	Hallman <i>et al.</i> , "Inositol supplementation in premature infants with respiratory distress syndrome," <i>N. Eng. J. Med.</i> , 326:1233-1239, 1992.
	C11	Hausheer <i>et al.</i> , "Karenitecins: a novel, potent class of oral highly lipophilic topo I inhibitors," <i>Proc. Annu. Meet. Am. Asoc. Cancer Res.</i> , 38:A1526, 1997.
	C12	Hertzberg <i>et al.</i> , "Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity," <i>J. Medic. Chem.</i> , 32:715-720, 1989.
	C13	Hochster <i>et al.</i> , "Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen," <i>J. Clin. Oncol.</i> , 12:553-559, 1994.
	C14	Iacono <i>et al.</i> , "Aerosol cyclosporin therapy in lung transplant recipients with bronchiolitis obliterans," <i>Eur. Respir. J.</i> , 23:384-390, 2004.
	C15	Kim <i>et al.</i> , "Pharmacodynamics of insulin in polyethylene glycol-coated liposomes," <i>Int. J. Pharm.</i> , 180:75-81, 1999.
↓	C16	Knight <i>et al.</i> , "New approaches in aerosol drug delivery for the treatment of asthma," in Allergy and Allergic Diseases, Kay (ed), Blackwell Publications, Oxford, England, I:730-741.

25695214.1

EXAMINER: /Aradhana Sasan/ DATE CONSIDERED: 01/17/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:158US	Serial No. 10/663,573
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant J. Vernon Knight <i>et al.</i>	
		Filing Date: September 16, 2003	Group: 1615
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
AS	C17	Lesueur-Ginot <i>et al.</i> , "Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties," <i>Cancer Res.</i> , 59:2939-2943, 1999.
	C18	Mi <i>et al.</i> , "Reduced albumin binding promotes the stability and activity of topotecan in human blood," <i>Biochemistry</i> , 34:13722-13728, 1998.
	C19	Ozer, "Stability studies of 5-FU liposomes," <i>Drug Targeting Delivery</i> , 1:151-160, 1992.
	C20	Schreier <i>et al.</i> , "Pulmonary delivery of liposomes," <i>J. Controlled Release</i> , 24:209-223, 1993.
	C21	Sugartman <i>et al.</i> , "Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies," <i>Cancer Chemother Pharmacol.</i> , 37:531-538, 1996.
	C22	Verschraegen <i>et al.</i> , "A phase I clinical and pharmacological study of oral 9-nitrocAMPOTHECIN, a novel water-insoluble topoisomerase I inhibitor," <i>Anti-Cancer Drugs</i> , 9:36-44, 1998.
	C23	Verschraegen <i>et al.</i> , "Alternative administration of camptothecin analogues," <i>Ann NY Acad. Sciences</i> , 922:237-246, 2000.
	C24	Waldrep <i>et al.</i> , "Cyclosporin A liposome aerosol: particle size and calculated respiratory deposition," <i>Int. J. Pharmaceutics</i> , 97:205-212, 1993.
	C25	Waldrep <i>et al.</i> , "Nebulized glucocorticoids in liposomes: aerosol characteristics and human dose estimates," <i>J. Aerosol Med.</i> , 7:133-145, 1994.
	C26	Weibel, "Geometry and dimensions of airways of conductive and transitory zones," In <i>Morphometry of the Human Lungs</i> , NY: Academic Press Inc., 110-140, 1963.
▼	C27	Zamboni <i>et al.</i> , "Phase I and pharmacokinetic (PK) study of intermittently administered 9-nitro-campotethcin (9NC, Rubitecan) in patients with advanced malignancies," <i>Proc. Am. Soc. Clin. Oncol.</i> , A411, 2001.

25695214.1

EXAMINER:	/Aradhana Sasan/	DATE CONSIDERED:	01/17/2007
-----------	------------------	------------------	------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.